Chronic hepatitis B infections on the rise since 2008
In 2017, the majority (58%) of the almost 27 000 newly reported hepatitis B cases in the European Union and European Economic Area were classified as chronic infections. This follows a consistent upward trend in reported chronic hepatitis B cases since 2008.
Influenza vaccination coverage rates insufficient across EU Member States
None of the European Union (EU) Member States could demonstrate that they reach the EU target of 75% influenza vaccination coverage for vulnerable groups, according to a new report from the European Centre for Disease Prevention and Control (ECDC).
Marking European Testing Week: ECDC issues integrated hepatitis and HIV testing Guidance
To mark European Testing Week from 23 to 30 November 2018, ECDC publishes its new Guidance on integrated viral hepatitis and HIV testing.
World Hepatitis Day 2018
On the occasion of World Hepatitis Day, ECDC launched online prevalence database for hepatitis B and C which included data mainly based on peer-reviewed cross sectional studies from 2006 onwards.
ECDC Expert meeting on non-pharmaceutical countermeasures for Pandemic flu
The meeting focused on the evidence base for the revision of the updated “Guide to public health measures to reduce the impact of influenza pandemics in Europe”, with a specific emphasis on non-pharmaceutical countermeasures for pandemic flu.
Public consultation on strengthening cooperation against vaccine-preventable diseases
The European Commission had an ongoing open public consultation on ‘strengthened cooperation against vaccine-preventable diseases’ which ran until 15 March 2018. The objective of this consultation was to collect the views and input of citizens, administrations, associations and other relevant organisations to feed into the process of drafting a proposal for a Council Recommendation to be adopted in mid-2018.
Expert panel reviews neuraminidase inhibitors for the prevention and treatment of influenza
An ECDC expert opinion concludes that there is clear evidence supporting the use of neuraminidase inhibitors in the treatment and prevention of influenza. Moreover, the current recommendations in European countries on the use of the neuraminidase inhibitors oseltamivir and zanamivir are appropriate and should be applied by prescribing physicians.